CP.TO 1.15VRT -18.06NVDA -7.33TSM -15.23JPM -6.1ZST.TO 0.01HSAV.TO -0.03HSUV.U.TO 0.03
Pfizer Inc (PFE)

NYSE:PFE

Pfizer Inc (PFE)

27.75
+0.03 (0.11%)
as of Sep 14, 2026, 5:42:20 pm Market Open.
583 watching
Icon Financials Financials Icon Analysis Technical Analysis
Interactive Chart
1w 1m 6m 1y
0
Investor Insights
star iconSep 14, 2026, 12:00 am

This summary was created by AI, based on 27 opinions in the last 12 months.

Pfizer Inc. (PFE) is perceived as a defensive stock with an attractive dividend yield around 6-7%, appealing to income-focused investors. However, many experts express concern about the company's growth potential following a reliance on COVID-19 vaccine revenues, which have receded. The consensus indicates that while PFE maintains a low valuation (PE around 8-10x), its growth is stagnant or uncertain due to impending patent expirations and the challenges associated with developing new blockbuster drugs. Moreover, there are worries that the ongoing focus on acquisitions may not lead to the anticipated revenue boosts. Despite these concerns, some analysts suggest PFE could still perform well for patient investors, especially as sector interest begins to build. Ultimately, the outlook remains cautious, with a preference noted for other stocks in the pharmaceutical sector that exhibit better growth trajectories.

consensus icon
Consensus
Cautious
valuation icon
Valuation
Undervalued
review icon
Similar
LLY
BUY

Pfizer Inc(PFE)

Jan 04, 2002
Likes the sector. Well positioned. Prefers over Merc.
Photo of John ZechnerJohn ZechnerUnlock Rating
$39.40

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 03, 2002
(Was a top pick on Sept 26 up 3.5%) Will have to buy some biotechs to keep their pipelines growing.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$39.70

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Jan 02, 2002
(Was a top pick on Sept 10 up 4.4%) Not the best time to buy pharmaceuticals. Buy under $40.
Photo of Brad WillockBrad WillockUnlock Rating
$39.90

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 28, 2001
Very expensive. US drug companies are having problems.
Photo of Brian Acker, CABrian Acker, CAUnlock Rating
$40.40

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Dec 19, 2001
Good cash flow. Will grow 20% + 2002/03 and 15% 2004. A good price.
Photo of Michelle CalpinMichelle CalpinUnlock Rating
$41.10

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Dec 17, 2001
Excellent company. Good dividends.
Photo of Bob StodgellBob StodgellUnlock Rating
$40.33

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
DON'T BUY

Pfizer Inc(PFE)

Dec 12, 2001
Great company, but economy is hitting all drug companies. Too high now.
Photo of Paul O'NeilPaul O'NeilUnlock Rating
$40.24

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Nov 28, 2001
(Was a top pick on Sept 26 up 16%) Still likes. A lot more upside yet.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$43.17

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Nov 28, 2001
Has a good pipeline for new drugs.
Photo of Mark Jackson, CFAMark Jackson, CFAUnlock Rating
$43.17

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY ON WEAKNESS

Pfizer Inc(PFE)

Nov 08, 2001
Good products. Buy on weakness.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$42.30

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 30, 2001
One of the best drug companies.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
PAST TOP PICK

Pfizer Inc(PFE)

Oct 30, 2001
(Was a top pick on April 12 up 4.6%) Good sector.
Photo of Neil MurdockNeil MurdockUnlock Rating
$42.45

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Oct 25, 2001
Trades in a range. Good company.
Photo of Brendan CaldwellBrendan CaldwellUnlock Rating
$43.01

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
BUY

Pfizer Inc(PFE)

Sep 27, 2001
Stable. Trading in the mid $20's is an earning multiple based on the 15% growth expected. Has competition.
Photo of Gordon Higgins, CA, MBAGordon Higgins, CA, MBAUnlock Rating
$39.75

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
TOP PICK

Pfizer Inc(PFE)

Sep 26, 2001
A defense stock. Ability to produce new drugs. Great patent protection. Great product line.
Photo of Joe ConnollyJoe ConnollyUnlock Rating
$38.55

Stock price when the opinion was issued

$27.74

As of Sep 14, 2026. Market Open.

biotechnologypharmaceutical
Showing 841 to 855 of 890 entries

Build your watch list

Sign in to track investments
you care about

Latest Buy Signals

DML.TO -0.18$4.01
BIR.TO 0.06$6.38
M 1.025$23.105
ZRE.TO 0.09$22.46
HMAX.TO -0.02$17.51

Today's Top Picks

CP.TO 1.15$124.99
VRT -18.06$239
NVDA -7.33$210.96
TSM -15.23$418.01
JPM -6.1$350.13

Popular Articles

Latest Sell Signals

XRE.TO 0.05$15.73
ORCL -5.49$144.79
ORCL -5.49$144.79
URI 8.38$997.5
BBD.B.TO 8.2$309.02

Most Recent Experts

Larry Berman CFA, CMT, CTA

Larry Berman CFA, CMT, CTA

ETF Capital Management Inc.

Jenny Harrington, CEO, Gilman Hill Asset Management

Jenny Harrington, CEO, Gilman Hill Asset Management

Gilman Hill Asset Management

Jim Lebenthal

Jim Lebenthal

Cerity Partners

Shannon Saccocia, CIO, Boston Private

Shannon Saccocia, CIO, Boston Private

Boston Private

Kevin Simpson

Kevin Simpson

Capital Wealth Planning

disclaimer

Stockchase, in its reporting on what has been discussed by individuals on business television programs (in particular Business News Network), neither recommends nor promotes any investment strategies.

We paraphrase the experts by hand, we watch the shows and write down what we understood from the experts’ comments. We are human and can make mistakes, help us fix any errors. If you see something that you know is not right or if there is a problem with the site, feel free to email us at: [email protected].

About usHow to useContact Us
More...
AdvertisingIn the newsPrivacy PolicyTerms of service
FacebookX
© 2000 - 2026 Stockchase Inc. by Wealthica
The ultimate 360° Tracker Your financial life in one place, automaticallywealthica-video

You may also like